Login / Signup

Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.

Richard B LiptonJoshua M CohenMaja GalicMichael J SeminerioPaul P YeungErnesto AycardiMarcelo E BigalKristen BibeauDawn C Buse
Published in: Headache (2021)
Fremanezumab demonstrated efficacy in the preventive treatment of CM and reduced headache impact in patients with comorbid depression.
Keyphrases
  • depressive symptoms
  • phase iii
  • sleep quality
  • open label
  • double blind
  • randomized controlled trial
  • phase ii
  • combination therapy
  • replacement therapy